A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1

Area of Science:

• Molecular Biology
• Cell Signaling
• Endocrinology

Background:

• Raf kinase is activated by growth factors, leading to extracellular regulated kinase 1/2 (Erk1/2) activation.
• All-trans retinoic acid (atRA) rapidly activates Erk1/2 in stem cells via cellular retinoic acid binding protein 1 (Crabp1).
• The precise mechanism of atRA-bound Crabp1's regulation of Erk1/2 activity was previously unclear.

Purpose of the Study:

• To identify the direct target of atRA-bound Crabp1 in the Erk1/2 signaling pathway.
• To elucidate the molecular mechanism by which Crabp1 modulates Raf kinase activity.
• To explore the therapeutic potential of targeting the atRA-Crabp1-Raf interaction.

Main Methods:

• Investigated Raf kinase as a direct target of atRA-Crabp1.
• Utilized Nuclear Magnetic Resonance (NMR) heteronuclear single quantum coherence (HSQC) analyses to determine the Crabp1-Raf interaction surface.
• Identified and tested a novel atRA-mimicking compound, C3, with Crabp1-selective activity.

Main Results:

• Crabp1 functions as an atRA-inducible scaffold protein for the Raf/Mek/Erk pathway, independent of growth factors.
• Crabp1 competes with Ras for binding to the Raf Ras binding domain (RBD), negatively modulating growth factor-stimulated Raf activation.
• atRA binding to Crabp1 enhances its inhibitory effect on Raf activation.
• NMR studies identified the 6-strand β-sheet face of Crabp1 as the Raf-interaction surface.
• The compound C3 demonstrated similar activity to atRA in modulating Crabp1's interaction with Raf.

Conclusions:

• This study uncovers a novel crosstalk between endocrine (atRA-Crabp1) and growth factor (Ras-Raf) signaling pathways.
• atRA-Crabp1 acts as a direct modulator of cell growth by targeting Raf kinase.
• Crabp1-selective compounds offer a potential therapeutic strategy to inhibit growth factor signaling while avoiding retinoid toxicity.